Loading
AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair.
Tilatamig samrotecan is AstraZeneca's bispecific antibody-drug conjugate that binds both EGFR and c-MET and delivers the topoisomerase I inhibitor AZ14170133 through a cleavable linker. Its low-affinity EGFR arm and high-affinity c-MET arm mean avidity biases delivery toward tumour cells co-expressing both receptors and spares normal tissue that expresses EGFR alone. It is in phase 2 in EGFR-mutant NSCLC after osimertinib and in EGFR-wild-type NSCLC, per AstraZeneca's 2026 pipeline, and is also being explored in head and neck cancer. Stomatitis, nausea, fatigue and neutropenia are the reported toxicities, and dose optimisation on an every-3-weeks schedule is under way. It is the most advanced of roughly 24 c-MET×EGFR ADC candidates, so its results will shape a crowded field. It is a two-address ADC meant to hit lung cancers carrying both EGFR and c-MET while sparing normal cells.
Tilatamig samrotecan carries a camptothecin-derived TOP1 inhibitor; exatecan shown as the class representative.
Bispecific EGFR/c-MET IgG with TOP1 payload; avidity-driven tumour selectivity. Connects to EGFR and MET.
1.Antibody binds EGFR and c-MET (bispecific) on the tumour cell surface
Source: clinicaltrials.gov/study/NCT05647122. Doses are for orientation; the current label governs.
| Adverse event |
|---|
| Stomatitis |
| Nausea |
| Fatigue |
| Neutropenia |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tilatamig samrotecan" OR ABSTRACT:"Tilatamig samrotecan" OR TITLE:"AZD9592" OR ABSTRACT:"AZD9592") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tilatamig samrotecan, not a curated reading list.
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Bispecific ADC.
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, AstraZeneca.
Shares MET, EGFR, Non-small-cell lung cancer.
Shares MET, EGFR, Non-small-cell lung cancer.
Shares MET, EGFR, Non-small-cell lung cancer.
Shares MET, Non-small-cell lung cancer.
Shares MET, EGFR, Non-small-cell lung cancer.
Shares MET, EGFR, Non-small-cell lung cancer.